DROSPIRENONE (Slynd®)
Clinical Indication
Oral POP
Comments
Restricted to women with endometriosis and those who are unable to tolerate side effects as a result of 1st and 2nd generation progestogens
Date of classification
September 2025
Green
Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.